"{\n \"business_address\": \"TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN, IRELAND L2 2\", \n \"business_phone_no\": \"269-673-8451\", \n \"ceo\": \"John T. Hendrickson\", \n \"cik\": \"0001585364\", \n \"company_url\": \"www.perrigo.com\", \n \"employees\": 13300, \n \"entity_legal_form\": \"PUBLIC LIMITED COMPANY\", \n \"entity_status\": \"ACTIVE\", \n \"hq_address1\": \"Treasury Building\", \n \"hq_address2\": \"Lower Grand Canal Street\", \n \"hq_address_city\": \"Dublin\", \n \"hq_address_postal_code\": \"D02 XN96\", \n \"hq_country\": \"Ireland\", \n \"hq_state\": null, \n \"inc_country\": \"Ireland\", \n \"inc_state\": null, \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Drug Related Products\", \n \"latest_filing_date\": \"2017-08-10\", \n \"legal_name\": \"PERRIGO Co plc\", \n \"lei\": \"549300IFOQS6R1QLY196\", \n \"long_description\": \"Perrigo Company plc, together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx), Specialty Sciences, and Other segments. The CHC segment offers OTC products in various categories, including analgesics, cough/cold/allergy/sinus, gastrointestinal, infant nutritional, smoking cessation, animal health, feminine hygiene, diabetes and dermatological care, diagnostic, scar management, and other healthcare products, as well as vitamins, minerals, and dietary supplements (VMS); and contract manufacturing services. It serves retail drug, supermarket, mass merchandise chains, and wholesalers through sales force and industry brokers. The BCH segment provides branded OTC products in the natural health and VMS; cough, cold, flu, and allergy; personal care and derma-therapeutics; lifestyle; pain relief, nasal decongestants, and cold sore management; and anti-parasite areas, as well as offers generic pharmaceutical products. It serves pharmacies, drug, and grocery stores through pharmacy sales force, as well as a network of pharmacists. The Rx segment offers generic and specialty pharmaceutical prescription drugs in various dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations; and ORx products. It serves wholesalers; retail drug, supermarket, and mass merchandise chains; hospitals; and pharmacies. The Specialty Sciences segment offers Tysabri to treat multiple sclerosis. The Other segment offers active pharmaceutical ingredients used by generic and branded pharmaceutical companies. The company was founded in 1887 and is headquartered in Dublin, Ireland.\", \n \"mailing_address\": \"515 EASTERN AVENUE, ALLEGAN MI 49010\", \n \"name\": \"Perrigo Company PLC\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000CNFQW6\", \n   \"composite_figi_ticker\": \"PRGO:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000CNFQW6\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"PRGO:US\", \n   \"figi_uniqueid\": \"EQ0010175500001000\", \n   \"last_crsp_adj_date\": \"2017-08-23\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"PERRIGO CO PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"PRGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F0G647\", \n   \"composite_figi_ticker\": \"PIG:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000F0G6R2\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"PIG:GF\", \n   \"figi_uniqueid\": \"EQ0010175500001001\", \n   \"last_crsp_adj_date\": \"2017-08-22\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO CO PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"PIG\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F0G647\", \n   \"composite_figi_ticker\": \"PIG:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000F0G9F9\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"PIG:GM\", \n   \"figi_uniqueid\": \"EQ0010175500001001\", \n   \"last_crsp_adj_date\": \"2017-08-14\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO COMPANY PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"PIG\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F0G647\", \n   \"composite_figi_ticker\": \"PIG:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000F0G8S7\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"PIG:GS\", \n   \"figi_uniqueid\": \"EQ0010175500001001\", \n   \"last_crsp_adj_date\": \"2017-08-23\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO COMPANY PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"PIG\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TMQ748\", \n   \"composite_figi_ticker\": \"PRGO:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBRN\", \n   \"figi\": \"BBG006TMQ748\", \n   \"figi_exch_cntry\": \"SW\", \n   \"figi_ticker\": \"PRGO:SW\", \n   \"figi_uniqueid\": \"EQ0000000036709972\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBRN\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO COMPANY PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"BRN\", \n   \"ticker\": \"IE00BGH1M568\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F0G647\", \n   \"composite_figi_ticker\": \"PIG:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000F0G6Z3\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"PIG:GD\", \n   \"figi_uniqueid\": \"EQ0010175500001001\", \n   \"last_crsp_adj_date\": \"2013-11-26\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO COMPANY PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"PGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F0G647\", \n   \"composite_figi_ticker\": \"PIG:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000F0G647\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"PIG:GR\", \n   \"figi_uniqueid\": \"EQ0010175500001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO COMPANY PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"PGO\"\n  }, \n  {\n   \"composite_figi\": \"BBG000F0G647\", \n   \"composite_figi_ticker\": \"PIG:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000F0GBD6\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"PIG:GB\", \n   \"figi_uniqueid\": \"EQ0010175500001001\", \n   \"last_crsp_adj_date\": \"2017-08-22\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO COMPANY PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"PIG\"\n  }, \n  {\n   \"composite_figi\": \"BBG000KZ2PZ3\", \n   \"composite_figi_ticker\": \"PRGO:IT\", \n   \"currency\": \"ILS\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XTAE\", \n   \"figi\": \"BBG000KZ2QB7\", \n   \"figi_exch_cntry\": \"IT\", \n   \"figi_ticker\": \"PRGO:IT\", \n   \"figi_uniqueid\": \"EQ0000000001664005\", \n   \"last_crsp_adj_date\": \"2017-08-24\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XTAE\", \n   \"primary_listing\": false, \n   \"security_name\": \"PERRIGO CO PLC\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S704D8\", \n   \"stock_exchange\": \"TASE\", \n   \"ticker\": \"PRGO\"\n  }\n ], \n \"short_description\": \"Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment includes the company's former segments, which are the Nutritionals and Israel Pharmaceuticals and Diagnostics business. The BCH segment consists of the Omega business. The Prescription Pharmaceuticals includes the Rx Pharmaceuticals business. The Specialty Sciences segment comprises of the assets, which focuses on the treatment of multiple sclerosis. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.\", \n \"sic\": 2834, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"PRGO\"\n}"